Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Prepaid Assets: 2017-2024

Historic Prepaid Assets for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $23.6 million.

  • Crinetics Pharmaceuticals' Prepaid Assets rose 214.47% to $46.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.9 million, marking a year-over-year increase of 214.47%. This contributed to the annual value of $23.6 million for FY2024, which is 51.61% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Prepaid Assets of $23.6 million as of FY2024, which was up 51.61% from $15.6 million recorded in FY2023.
  • Crinetics Pharmaceuticals' 5-year Prepaid Assets high stood at $23.6 million for FY2024, and its period low was $6.6 million during FY2020.
  • Its 3-year average for Prepaid Assets is $16.7 million, with a median of $15.6 million in 2023.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Prepaid Assets soared by 66.56% in 2021, and later decreased by 2.31% in 2022.
  • Crinetics Pharmaceuticals' Prepaid Assets (Yearly) stood at $6.6 million in 2020, then surged by 66.56% to $11.0 million in 2021, then decreased by 2.31% to $10.8 million in 2022, then surged by 44.98% to $15.6 million in 2023, then surged by 51.61% to $23.6 million in 2024.